Dispatch Biotherapeutics

Dispatch Biotherapeutics

Cloud-based software linking labs and providers

Overview

Dispatch Bio provides a cloud-based software platform for infectious disease diagnostics. It connects patients, providers, and laboratories to deliver faster, more accurate test results. The core product is a SaaS system that laboratories use to manage test orders, workflows, and results reporting, while healthcare providers use it to order tests and receive timely results for patients. The platform integrates the entire diagnostic process in a single system, reducing turnaround times and streamlining communication across the care team. Compared with typical lab software, Dispatch Bio focuses on end-to-end workflow integration, strong data security and regulatory compliance, and a B2B model that targets diagnostic labs and healthcare providers. Its goal is to modernize diagnostic testing to enable quicker diagnoses and better patient management in infectious diseases.

About Dispatch Biotherapeutics

Simplify's Rating
Why Dispatch Biotherapeutics is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Enterprise Software

Healthcare

Company Size

51-200

Company Stage

Series A

Total Funding

$216M

Headquarters

Philadelphia, Pennsylvania

Founded

2022

People at Dispatch Biotherapeutics

People at Dispatch Biotherapeutics who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA cleared IND for DISP-10 enabling Phase 1 trial in solid tumors starting patient recruitment in 2026.
  • The $216 million Series A funding led by Arch Venture Partners and Parker Institute supports universal solid tumor treatment development.
  • Clinical collaboration with CARsgen enables DISP-11 Phase 1 trial in China beginning 2026 leveraging Flare platform with zevorcabtagene autoleucel.

What critics are saying

  • Phase 1 trial of DISP-10 fails in gastrointestinal cancers halting development and destroying investor confidence within 12 to 18 months.
  • Bristol Myers Squibb terminates ide-cel supply causing over six month delay in patient recruitment for DISP-10 trial within 9 to 12 months.
  • FDA mandates additional preclinical toxicity data for DV-10 virus stalling Phase 1 expansion and funding runway within 6 to 9 months.

What makes Dispatch Biotherapeutics unique

  • Dispatch Bio's Flare platform uses a tumor-specific virus to paint synthetic antigens enabling precise T cell recognition in solid tumors.
  • The company combines immunotherapy with engineered tumor-targeted viruses to remodel the immunosuppressive microenvironment and drive robust CAR T function.
  • DISP-10 pairs DV-10 virus with BCMA-directed CAR T therapy ide-cel to create optimal biological context for solid tumor clearance.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$216M

Above

Industry Average

Funded Over

1 Rounds

Series A funding typically happens when a startup has a product and some customers, and now needs funding to scale. This money is usually used to grow the team, expand marketing, and improve the product. Venture capital firms are frequently the main investors here.
Series A Funding Comparison
Above Average

Industry standards

$15M
$8.2M
Discord
$15M
Canva
$30M
Kalshi
$216M
Dispatch Biotherapeutics

Benefits

Health Insurance

Vision Insurance

Dental Insurance

Life Insurance

Unlimited Paid Time Off

Growth & Insights

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%

Recently Posted Jobs

Sign up to get curated job recommendations

Dispatch Biotherapeutics is Hiring for 6 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →